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Abstract
Purpose: Fanconi anemia is an inherited disorder associated
with a constitutional defect in the Fanconi anemia DNA repair
machinery that is essential for resolution of DNA interstrand
crosslinks. Individuals with Fanconi anemia are predisposed to
formation of head and neck squamous cell carcinomas (HNSCC)
at a young age. Prognosis is poor, partly due to patient intolerance
of chemotherapy and radiation requiring dose reduction, which
may lead to early recurrence of disease.
Experimental Design: Using HNSCC cell lines derived from
the tumors of patients with Fanconi anemia, andmurine HNSCC
cell lines derived from the tumors ofwild-type and Fancc/mice,
we sought to deﬁne Fanconi anemia–dependent chemosensitivity
and DNA repair characteristics. We utilized DNA repair reporter
assays to explore the preference of Fanconi anemia HNSCC cells
for non-homologous end joining (NHEJ).
Results: Surprisingly, interstrand crosslinker (ICL) sensitivitywas
notnecessarily Fanconi anemia–dependent inhumanormurine cell
systems. Our results suggest that the increased Ku-dependent NHEJ
that is expected in Fanconi anemia cells did notmediate relative ICL
resistance. ICL exposure resulted in increased DNA damage sensing
and repair by PARP in Fanconi anemia–deﬁcient cells. Moreover,
human and murine Fanconi anemia HNSCC cells were sensitive to
PARP inhibition, and sensitivity of human cells was attenuated by
Fanconi anemia gene complementation.
Conclusions: The observed reliance upon PARP-mediated
mechanisms reveals a means by which Fanconi anemia HNSCCs
can acquire relative resistance to the ICL-based chemotherapy that
is a foundation of HNSCC treatment, as well as a potential target
for overcoming chemoresistance in the chemosensitive individ-
ual. Clin Cancer Res; 21(8); 1962–72. 2015 AACR.
Introduction
Fanconi anemia is a genetic disorder characterized by congen-
ital abnormalities, progressive bone marrow failure, and cancer
predisposition (1, 2). Fanconi anemia results from germ-line
mutations in one of 16 genes that participate in a common DNA
repair pathway, thus deregulating DNA damage responses and
leading to the disorder's clinical phenotypes (3–5). It has been
demonstrated that Fanconi anemia–deﬁcient cells exhibit
reduced capacity for homologous recombination (HR), whereas
non-homologous end joining (NHEJ) is elevated and even func-
tionally contributes to Fanconi anemia phenotypes under certain
circumstances (6, 7). Although acute myelogenous leukemia
(AML) is the most frequently occurring malignancy in Fanconi
anemia, individuals with the disease also possess a strong pre-
disposition to the development of solid tumors, particularly
squamous cell carcinomas of the head and neck (HNSCC), as
well as of the anogenital region (8–11). Fanconi anemia HNSCCs
occur primarily in the oral cavity and in the absence of traditional
risk factors for HNSCC such as tobacco and alcohol use (11, 12).
Data from the International Fanconi Anemia Registry indicate
that the cumulative incidence of nonhematologicmalignancies in
patients with Fanconi anemia may be as high as 28% by 40 years
of age (11). This dramatic risk of HNSCC is, for unclear reasons,
increased further by the allogeneic hematopoietic stem cell trans-
plantation that is the treatment of choice to correct the disorder's
progressive bone marrow failure (13, 14). The hypothetical
cumulative incidence of HNSCC, deﬁned as the cumulative
incidence of HNSCC development if the competing risks of death
due to other causes are removed, has been estimated to approach
100% in transplanted patients versus 50% in nontransplanted
patients that reach their maximal life expectancy (14). Thus, as
improved transplantation and supportive care measures prolong
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survival, the risk of HNSCC will become an increasingly prom-
inent issue for patients with Fanconi anemia.
Once HNSCCs are clinically manifest, patients with Fanconi
anemia fare exceedingly poorly with 2-year overall and relapse-
free survival rates of less than 50% (15). Patients tolerate surgery
well, but experience signiﬁcant morbidity and alsomortality with
the radiation and/or interstrand crosslinker (ICL)–based chemo-
therapy that, dependingupon tumor stage at presentation,maybe
necessary components of treatment (12, 15, 16). Although the
poor prognosis of patients with Fanconi anemiaHNSCChas been
attributed to intolerance of conventional clastogenic therapy due
to their constitutional sensitivity to DNA damaging agents, a high
rate of early locoregional recurrence (15) may suggest that the
tumors are not adequately controlled by the degree of genotoxic
therapy that they can tolerate.
The desire to avoid severe toxicity and the hope that Fanconi
anemia HNSCCs will share in the individual's DNA damage
sensitivity make the use of low-dose clastogenic treatments a
possible option for therapy. However, the increased genomic
instability caused by an underlying defect in error-freeDNA repair
by HR may facilitate Fanconi anemia tumor evolution by induc-
ing genomic adaptations that could mitigate any inherent sensi-
tivity toDNAdamage, particularly in light of the ability of Fanconi
anemia–deﬁcient oral keratinocytes to proliferate more rapidly
compared with controls, despite exhibiting increased DNA dam-
age both in vitro and in vivo (17, 18). Thus far, the extent to which
Fanconi anemia HNSCC phenotypes remain dependent on a
dysfunctional Fanconi anemia pathway remains unclear, and
direct and systematic examination of Fanconi anemia–dependent
biologic and molecular properties of Fanconi anemia HNSCCs
has been limited (19, 20), predominantly due to the paucity of
available isogenic human and murine HNSCC model systems.
The PARP family of proteins contains 18 distinct proteins that
catalyze the covalent attachment of ADP-ribose units from donor
NADþmolecules onto target proteins, resulting in the attachment
of monomers or linear or branched poly(ADP-ribose) (PAR)
polymers that modify the receiving protein's function (21, 22).
Twoof these, PARP1andPARP2, bind to sites ofDNAdamage and
recruit and activate effector proteins that participate in numerous
DNA damage repair mechanisms. PARP1 has also been shown to
PARylate itself as a means of enhancing its own activity (21, 22).
AlthoughPARPproteins havebeen implicated in chemoresistance
of several solid tumor types, including non–small cell lung cancer
and sporadic head and neck cancers (23, 24), and their inhibition
has been associated with synthetic lethality in tumor cells defec-
tive in BRCA1 or BRCA2 (25), they have not yet been studied in
Fanconi anemia HNSCC.
To characterize the pathway-dependent cellular and molecular
phenotypes of Fanconi anemia HNSCC cells, we generated iso-
genic cellular models of Fanconi anemia–deﬁcient and proﬁcient
HNSCC cells, and characterize here their comparative biologic
and molecular properties and DNA repair capabilities. Human
patient-derived FANCA/ and FANCC/ HNSCC cells were
transduced with either control or Fanconi anemia–complement-
ing retroviral vectors before analysis. Surprisingly, ICL sensitivity
of Fanconi anemia–deﬁcient tumor cells was not increased com-
pared with their Fanconi anemia–complemented cellular coun-
terparts or to sporadicHNSCCcells. In addition, amurineHNSCC
model was generated by exposing wild-type (WT) and Fancc/
mice to the carcinogen 4-nitroquinolone 1-oxide (4-NQO).
Although non-neoplastic Fancc/ epithelial cells were hypersen-
sitive to crosslinking agents, some Fancc/ tumor cells lost their
characteristic sensitivity, similar to the human model. To inves-
tigate potential compensatory mechanisms in DNA repair path-
ways of Fanconi anemia HNSCCs, we tested the degree to which
PARP proteins are engaged in the repair process in both Fanconi
anemia–proﬁcient and Fanconi anemia–deﬁcient cells. The
results show that PARP activity is speciﬁcally upregulated in
Fanconi anemia–deﬁcient HNSCCs, and this increased activity
is associated with a selective sensitivity to PARP inhibitors in both
humanandmurine Fanconi anemiaHNSCCcells. Taken together,
the data question the expectation that Fanconi anemia HNSCCs
share the individual's global DNA damage hypersensitivity, thus
perhaps contributing to the high rate of early locoregional recur-
rence in patients treated with reduced-intensity genotoxic thera-
pies. Importantly, we also demonstrate that this increased resis-
tance to ICLs is caused, at least in part, through PARP activation.
PARP inhibitors may thus provide new avenues for treatment of
HNSCC in Fanconi anemia.
Materials and Methods
Human cell cultures and vectors
Three Fanconi anemia patient–derived HNSCC cell lines used
in this study were kind gifts from other institutions. VU-1131
(FANCC/) and VU-1365 (FANCA/) lines were obtained from
Drs. Johan de Winter and Ruud Brakenhoff at VU University,
Amsterdam, the Netherlands, and OHSU-974 (FANCA/) cells
were obtained from Dr. Grover Bagby at the Oregon Health and
ScienceUniversity (OHSU). These havebeendescribed previously
as human papillomavirus (HPV)–negative head and neck cancer
cells, and the respective patients were not treated with cisplatin or
other ICL-causing agents before creation of the cell lines (19).
Human sporadic HNSCC cell lines CAL-27, FADU, and SCC-4
were obtained from the American Type Culture Collection. Cell
culture conditions are detailed in Supplementary Materials and
Methods. All cell lines were authenticated regularly by their
Translational Relevance
Because of the sensitivity of patientswith Fanconi anemia to
DNA damage caused by interstrand crosslinks, current therapy
for head and neck squamous cell carcinomas (HNSCC) devel-
oping in patients with Fanconi anemia requires either dose
reduction or omission of the radiotherapy and chemotherapy
that are mainstays of treatment for sporadically occurring
HNSCCs. However, frequent early locoregional recurrence
suggests a discontinuity between constitutional DNA damage
sensitivity and tumor cell chemotherapy sensitivity. The sur-
prising degree of interstrand crosslinker (ICL) resistance of
Fanconi anemia HNSCC cells questions the efﬁcacy of low-
dose conventional therapies. By identifying sensitivity to PARP
inhibitors, this study demonstrates that systematic testing of
alternative agents will be necessary using our established
murine and human Fanconi anemia HNSCC models, and
that results obtained from these studies may be directly
translatable into phase I/II clinical trials for treatment of
Fanconi anemia HNSCC using PARP inhibition via either
systemic or directed means.
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morphologic characteristics and analysis of Fanconi anemia status
and corresponding genetic and molecular markers.
The cDNAs for humanFANCA and FANCCwere cloned into the
multicloning site of the oncoretroviral vector S91IN, which coex-
presses an IRES-neomycin phosphotransferase cassette, thus con-
ferring resistance to G418 (Invitrogen). S91IN and the two Fan-
coni anemia vectors, S91FAINandS91FCIN,were transfected into
ecoPhoenix cells and then supernatant generated to stable trans-
duce PG13 cells, as previously described (26, 27). Supernatant
from G418-resistant PG13 cells were collected, ﬁltered through
0.45 mm, stored at 80C, thawed, and then tested functionally
for correction of FANCA- and FANCC-deﬁcient reference cells
with known bi-allelicmutations (data not shown). Subsequently,
supernatants were utilized to transduce humanHNSCC cell lines.
Cultureswith 0.8mg/mLmediumG418were used for selection of
transduced polyclonal HNSCC cell populations.
Murine HNSCC tumor induction
Fancc/ mice were described previously (28) and were main-
tained and treated according to Institutional Animal Care andUse
Committee guidelines at the Portland VA Medical Center. To
generate murine oral HNSCCs, 2- to 4-month-old mice (22 WT
and 18 Fancc/) were treated with 20 mg/mL 4-NQO (Sigma) in
water for up to 45 weeks. Mice were monitored weekly for tumor
development and euthanized at the ﬁrst signs of morbidity.
Following euthanasia, tumor masses were preserved in formalin
for histologic analyses and/or prepared for cell isolation and
culture. Tumor grade and type were determined by hematoxylin
and eosin (H&E) staining and analysis by a cancer pathologist at
OHSU blinded to the genotype of the specimens.
Murine cell culture
Cell isolation and culture of primary tongue epithelial cells and
HNSCC cells from WT and Fancc/ mice are described in Sup-
plementary Materials and Methods.
Western blot analysis
Trypsinized cells were washed with PBS and collected by
centrifugation. For FANCA, FANCC, FANCD2, and actin immu-
noblots, whole-cell protein extracts were lysed using the Laemmli
method (29). For DNA-PKcs and pDNA-PKcsS2056 immunoblots,
whole-cell protein extracts were lysed using RIPA buffer (1%
Triton X-100, 1% DOC, 0.1% SDS, 0.16 mol/L NaCl, 10
mmol/L Tris, pH 7.4, and 5 mmol/L EDTA) supplemented with
a protease inhibitor cocktail (BD Biosciences), 10 mmol/L NaF,
and 5 mmol/L NaVO3. Protein concentrations were determined
using a Pierce BCA Protein Assay kit (Thermo Scientiﬁc). Lysates
were resolved by SDS–PAGE. Proteins were transferred to a
polyvinylidene diﬂuoride membrane (BioRad). Membranes were
probedwith the appropriate primary antibody overnight. Primary
antibodies used were as follows: FANCA (Cascade), FANCC (a
kind gift from the Fanconi Anemia Research Fund through
OHSU), FANCD2 (Novus), actin (Seven Hills Bioresearch),
DNA-PKcs (Abcam), and pDNA-PKcsS2056 (Abcam). Membranes
were washed with TNET (10mmol/L Tris, 2.5mmol/L EDTA,
50mmol/L NaCl, and 0.1% Tween 20), and secondary anti-
mouse (GE) or anti-rabbit (Jackson Immunoresearch) antibodies
conjugated to horseradish peroxidase were added for 30minutes.
Membranes were then exposed to chemiluminescence reagents
(Thermo Scientiﬁc) for protein detection. For detection of mono-
ubiquitinated FANCD2, cells were plated for 24 hours and sub-
sequently left untreated or treatedwith 2mmol/L hydroxyurea for
24 hours before collection. For detection of DNA-PKcs and
pDNA-PKcsS2056, cells were pretreated with DNA-PKcs inhibitors
DNA-PK inhibitors NU-7026 (Tocris) or NU-7771 (Tocris) for 24
hours and subsequently with 2 mg/mL bleomycin for 20 minutes
before collection.
Organotypic epithelial raft culture
Three-dimensional organotypic rafts were generated as
described previously and as detailed in Supplementary Materials
andMethods (18). H&E staining was performed for morphologic
examination by a cancer pathologist at Cincinnati Children's
Hospital Medical Center blinded to the gene complementation
status of the specimens. Photographs were obtained on a Leica
DM2500 microscope using Leica Application Suite software.
Immunoﬂuorescence for BrdUrd was performed as described
below. The percentage of BrdUrd-positive cell population was
quantiﬁed as the ratio of total BrdUrd-positive nuclei to total
nuclei per 200 ﬁeld. Such ratios were determined for three ﬁelds
of each raft and averaged.
Immunoﬂuorescence microscopy
Preparation of coverslips and epithelial raft sections for immu-
noﬂuorescence and performance of immunoﬂuorescencemicros-
copy is described in Supplementary Materials and Methods.
Cell cycle analysis by ﬂow cytometry
Assays were performed as previously described (30). Brieﬂy,
Fanconi anemia–deﬁcient and –complemented HNSCC cells
were either left untreated or treated with 0.25mg/mL melphalan
(Sigma) for 48 hours. Cells were trypsinized, washed in PBS, and
ﬁxed in 100mLBDCytoﬁx/Cytoperm (BDBiosciences). Cellswere
prepared using the protocol for the APC BrdU Flow Kit (BD
Biosciences). Cell cycle proﬁles were detected using 7AAD on a
BD FACSCanto instrument (BD Biosciences), and these data were
analyzed using FlowJo software (Tree Star).
Cellular proliferation assays
Cellular growth was measured byMTS assays as described (31)
and by viable cell counts over time using dye exclusion and
counted live cell assays as described in Supplementary Materials
and Methods.
DNA repair assays
Flow cytometry–based DNA repair assays were performed as
described (32) using constructs designed to measure the propor-
tion of cells engaged in NHEJ. Brieﬂy, equal numbers of Fanconi
anemia–deﬁcient and –complemented VU-1131 cells were plated
in 6-well plates. Following 24 hours of growth, transfections were
performed utilizing FuGENE HD transfection reagent (Promega)
and Opti-MEM reduced serum media (Invitrogen). Following
24 hours, GFP expression was measured using a BD FACSCanto
instrument (BD Biosciences). These data were analyzed using
FlowJo software (Tree Star). At least four independent experi-
ments were performed with each construct.
Statistical analysis
Graphs were created and statistical analyses performed using
GraphPad Prism software (GraphPad). Data points and error bars
indicate mean and SD, respectively, of the raw data.
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Results
Fanconi anemia complementation of patient-derived HNSCC
cells reverses characteristic cellular Fanconi anemiaphenotypes
The goal of this study was to determine Fanconi anemia–
dependent growth and chemosensitivity properties of patient-
derived HNSCC cells, with the expectation that substantial ICL
sensitivity was to be observed in Fanconi anemia–deﬁcient
cells. One FANCC-deﬁcient cell line (VU-1131) and two
FANCA-deﬁcient cell lines (OHSU-974 and VU-1365), all orig-
inally cultured from the HNSCCs of patients with Fanconi
anemia, were utilized for gene correction. The cells were trans-
duced with either control retroviral vector, FANCC retroviral
vector for VU1131, or FANCA vector for OHSU-974 and VU-
1365. FANCA and FANCC expression was conﬁrmed in each
case at the protein level by immunoblotting. Complementation
restored pathway activation as demonstrated by FANCD2
monoubiquitination following HU treatment; thus, the mutant
Fanconi anemia gene was corrected in each case (Fig. 1A). In
addition, immunoﬂuorescence experiments demonstrated that
monoubiquitinated FANCD2 in complemented, but not control
cells, was capable of localizing to sites of double-stranded DNA
breaks following mitomycin C (MMC) treatment as shown by
colocalization of FANCD2 and gH2AX foci (Fig. 1B). To verify
Fanconi anemia pathway functionality, isogenic cell populations
were treated with melphalan and subjected to cell cycle analysis.
As predicted, Fanconi anemia complementation rescued cells
from accumulation in theG2–Mphase of the cell cycle, a hallmark
of Fanconi anemia pathway deﬁciency, following melphalan
treatment (Fig. 1C; ref. 30).
Fanconi anemia complementation does not affect HNSCC
proliferation in three dimensions
Our previous work utilizing HPV E6/E7-immortalized Fanconi
anemia patient–derived and Fanconi anemia knockdown kerati-
nocyte models had shown that Fanconi anemia loss confers a
proliferative advantage, speciﬁcally in the environment of three-
dimensional organotypic epithelial rafts, despite characteristic
Fanconi anemia phenotypes and increased DNA damage (18).
To examine the growth of Fanconi anemia HNSCC in the context
of the epithelial milieu wherein they arise, we generated rafts
utilizing the above Fanconi anemia–deﬁcient and –complemen-
ted HNSCC cells. H&E staining revealed comparable raft thick-
ness, as well as similar morphologic features of the constituent
cells (Fig. 2A). Immunoﬂuorescence detection of BrdUrd incor-
poration revealed no signiﬁcant differences, indicating that Fan-
coni anemia correction in malignant HNSCC cells does not affect
proliferation (Fig. 2B). From this, we concluded that although
differentiation-associated cell cycle exit of non-malignant, HPV-
positive keratinocytes is Fanconi anemia–dependent and
Figure 1.
Gene correction of Fanconi anemia (FA) patient–derived HNSCC cell lines. A, immunoblot of isogenic Fanconi anemia patient–derived HNSCC cell lines.
Complementation of the relevant Fanconi anemia gene restores FANCD2 activity upon treatment with hydroxyurea (HU). FAmut, Fanconi anemia–deﬁcient;
FAcomp, Fanconi anemia–complemented; S, FANCD2; L, monoubiquitinated FANCD2. B, immunoﬂuorescence for FANCD2 and gH2AX shows localization of
FANCD2 to sites of DNAdamage in FAcompcells followingmitomycinC (MMC) treatment. Images shown are representative of three independent experiments, each
with similar results. C, FAcomp cells are rescued from cell cycle arrest in the G2–M phase caused by melphalan treatment.
Chemoresistance in Fanconi Anemia Head and Neck Cancers
www.aacrjournals.org Clin Cancer Res; 21(8) April 15, 2015 1965
reversible upon complementation, the Fanconi anemia pathway
is unable to exert any such antiproliferative inﬂuence following
tumorigenesis.
Fanconi anemia HNSCC cells acquire relative resistance to ICLs
The expectation that Fanconi anemia–deﬁcient HNSCC cells
possess the same hypersensitivity to ICLs as nonmalignant cells
frompatientswith Fanconi anemia has not previously been tested
in murine or human systems. We therefore sought to develop a
murine model of nonmalignant oral keratinocytes and HNSCCs
using Fancc/ and WT mice. Oral keratinocytes were harvested
from either WT (W-NR) or Fancc/ (M-NR) mice, SV40-trans-
duced for immortalization, and analyzed in survival assays to test
for relative sensitivities to MMC and cisplatin. As expected, SV40-
immortalized Fancc/ oral keratinocytes exhibited signiﬁcantly
increased sensitivity to MMC and cisplatin when compared with
their WT counterparts (Fig. 3A). Speciﬁcally, Fancc/ cells dis-
played an approximately 5-fold average decrease in half maximal
effective concentration (EC50) compared with WT cells (Fig. 3B;
Supplementary Table S1).
For HNSCC induction, we utilized awell-known carcinogen, 4-
NQO,which has been shown to cause the development ofmurine
HNSCCs that closely mimic human tumors histopathologically
(33, 34).WT and Fancc/micewere treatedwith 4-NQO inwater
for up to 45weeks. Mice weremonitored weekly for visible tumor
development and euthanized at the ﬁrst signs of morbidity.
Survival (time tomorbidity that necessitated sacriﬁce) and tumor
incidence were similar forWT and Fancc/mice (Supplementary
Fig. S1A and S1B). Median survival for both cohorts of mice was
40 weeks. Greater than 80% ofmice of both genotypes developed
tumors that were located mainly on the tongue, with a subset
developing on or in the lip, buccal mucosa, and esophagus
(Supplementary Fig. S1C). All tumors were well-differentiated
HNSCCs, ranging from low- to high-grade (Supplementary Fig.
S1D and Supplementary Table S1). We did not detect metastases
in either genotype, analogous to previous studies (33, 34), per-
haps due to the necessity of early euthanasia after tumor devel-
opment. Tumors were harvested for generation ofWT (W-SCC) or
Fancc/ (M-SCC) cell lines. These were subsequently tested in
survival assays for relative sensitivities to MMC and cisplatin.
Interestingly, Fancc/ mutant compared with WT HNSCC cells
did not differ signiﬁcantly in their sensitivity to MMC or cisplatin
(Fig. 3C). In fact, three of six WT lines displayed an MMC EC50 of
10 to 20 nmol/L, similar to an EC50 of 5 to 20mmol/L in Fancc
/
lines, whereas one otherWT line displayed an only slightly higher
EC50 of 29 nmol/L (Fig. 3D; Supplementary Table S1). The lack of
uniform ICL sensitivity in Fancc/ versus WT cell lines does not
appear to be due to increased chromosomal instability inWT cells
during malignant transformation, as Fancc/ cell lines showed
more complex karyotypes and had greater levels ofMMC-induced
chromosomal breakage (Supplementary Table S1).
To compare the murine with human Fanconi anemia HNSCC
cell models, we also subjected uncorrected Fanconi anemia
patient–derived cell lines and cell lines derived from sporadically
occurring HNSCCs to MMC treatment and performed viable cell
counts after 5 days of exposure. These experiments revealed results
similar to those obtained with murine HNSCC cells; overlap of
survival curves of Fanconi anemia and sporadic cell lines was
Figure 2.
Three-dimensional organotypic epithelial rafts generated from human Fanconi anemia (FA) HNSCC cells. A, H&E and immunoﬂuorescence staining of rafts created
from isogenic HNSCC cell lines. Images are representative of three independent experiments, each with similar results. H&E sections of FAmut and FAcomp
rafts are equivalent in mitotic index, cellular differentiation, and stromal content. Immunoﬂuorescence for BrdUrd incorporation indicates similar proliferative rates.
B, quantiﬁcation of BrdUrd incorporation of FAmut and FAcomp cells; a t test indicated no signiﬁcant difference.
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observed, and two of three Fanconi anemia and two of three
sporadic lines had an EC50 of 9 to 17 nmol/L (Fig. 4A and B).
Taken together, we concluded that Fanconi anemia–deﬁcient
HNSCC cells can largely overcome Fanconi anemia–dependent
sensitivity to chemical crosslinkers.
Fanconi anemia HNSCC cells engage in increased NHEJ at
baseline, but do not require Ku-dependent NHEJ for repair of
cisplatin-induced DNA damage
Given the reported stimulation of NHEJ that is regulated by
Fanconi anemia in other cellular models (6, 7), we next sought to
deﬁne Fanconi anemia–dependent NHEJ DNA repair properties
of Fanconi anemia HNSCC using established reporter constructs
(Fig. 5A). Isogenic VU-1131 cell lines were cotransfected with I-
SceI endonuclease plus NHEJ-GFP reporter plasmids as described
in mammary epithelial cell lines (32). Flow cytometry was then
used todetect thepercentage of cellswith the corresponding repair
events. As expected, Fanconi anemia HNSCC cells had signiﬁ-
cantly increased occurrences of NHEJ in comparison with their
complemented counterparts (Fig. 5B).
NHEJ has been identiﬁed as encompassing two distinct and
competing pathways (35). Classical NHEJ is dependent upon
recruitment of the Ku70/80 heterodimer to DNA double-strand
breaks (DSB) and subsequent activation by phosphorylation of
DNA-PKcs (36); alternative NHEJ is suppressed by the binding of
Ku70/80 to DSBs and is initiated by binding of PARP1 to DSB
ends (37, 38). The performance of Ku-dependent NHEJ has been
implicated in the increased defective DNA repair that occurs in
Fanconi anemia–deﬁcient cells (6, 7). To determine whether
Fanconi anemia HNSCC cells relied upon increased performance
of Ku-dependent NHEJ in response to ICLs, we next investigated
the effect of its inhibition using the DNA-PKcs inhibitors NU-
7026 and NU-7441 on cisplatin sensitivity of human Fanconi
anemia–deﬁcient and –complemented cell populations. We
hypothesized that, if Ku-dependent NHEJ were the necessary
DNA repair pathway used by Fanconi anemia HNSCC cells
following ICL exposure, then inhibition would produce an early
decrease in survival in deﬁcient versus complemented cells. To
understand baseline behavior, isogenic cell lines were ﬁrst treated
with cisplatin alone for two days, following which growth was
quantiﬁed by MTS assays. Fanconi anemia–deﬁcient and cor-
rected cells for each donor possessed similar sensitivities (Sup-
plementary Fig. S2A). Viable cell counts following 2 days ofMMC
treatment of VU-1131 and OHSU-974 cell lines also revealed
comparable survival (Supplementary Fig. S2B). Sensitivity to
other chemotherapeutic agents that are used clinically for the
treatment of head and neck cancer was also evaluated, including
paclitaxel, 5-ﬂuorouracil, and rapamycin. No differences in the
response to these drugs were observed between Fanconi anemia–
deﬁcient versus proﬁcient cells (Supplementary Fig. S2C and
S2D). Reduced DNA-PKcs phosphorylation in the presence of
NU-7026 or NU-7441 was conﬁrmed via immunoblotting (Fig.
5C; Supplementary Fig. S3A). Next, the cells were exposed to
cisplatin, and treated versus untreated cells were subjected to
cellular growth assays. Interestingly, DNA-PKcs inhibition did
not differentially affect the cisplatin sensitivity of Fanconi ane-
mia–deﬁcient and–complemented humanHNSCCcells (Fig. 5D;
Supplementary Fig. S3B), suggesting that Ku-dependent NHEJ
was not speciﬁcally upregulated by Fanconi anemia HNSCC cells
following ICL exposure.
Figure 3.
ICL sensitivity of murine Fanconi anemia HNSCC. A, cisplatin (left) and MMC (right) cellular growth assays of immortalized, nonmalignant oral epithelial cells of
Fancc/ (M-NR) andWT (W-NR)mice show signiﬁcantly increased sensitivity of Fancc/ cell lines. B, MMCEC50s of immortalized, nonmalignantmurine Fancc
/
andWT oral epithelial cells.  , P <0.01 (t test). C, cisplatin (left) andMMC (right) cellular growth assays of murine Fancc/ (M-SCC) andWT (W-SCC)mice indicate
overlap of sensitivities. D, MMC EC50s of Fancc
/ and WT HNSCC cell lines following 5 days of exposure; a t test revealed no signiﬁcant difference.
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PARPactivity is requiredbyFanconi anemiaHNSCC, and tumor
cells are sensitive to PARP inhibitors
PARP inhibitors were initially developed as chemotherapeu-
tic agents for BRCA-deﬁcient cancers following the identiﬁca-
tion of synthetic lethality of PARP inhibition in BRCA1-mutat-
ed cells (39). In light of the intrinsic relationship between the
Fanconi anemia and BRCA pathways, we sought to determine
the effect of PARP inhibition on the growth of Fanconi anemia
HNSCC cells. Viable cell counts were taken over time in the
presence of the combined PARP1/PARP2 inhibitor olaparib
and the PARP1 inhibitor PJ-34. The results indicated profound
sensitivity of human Fanconi anemia HNSCC cells to olaparib
that was signiﬁcantly decreased by complementation (Fig. 6A).
A similar result was observed in VU-1131 cells treated with PJ-
34 (Supplementary Fig. S4A). Intranuclear PAR foci, but not
cytoplasmic signal, are an indicator of PARP-mediated DNA
damage sensing and repair activity (40). Thus, we next quan-
tiﬁed PAR polymer foci following MMC treatment, and
detected increased formation of intranuclear PAR foci in Fan-
coni anemia–deﬁcient cells (Fig. 6B and C). To test olaparib
sensitivity in the above malignant murine tumor cell system,
we quantiﬁed viable cell counts using WT and Fancc/ cell
lines. PARP inhibitor sensitivity was present uniformly in the
Fancc/ cell lines (Fig. 6D; Supplementary Fig. S4B). Taken
together, activation of PARP-mediated DNA damage responses
provides a mechanism upon which Fanconi anemia HNSCC
cells can rely for response to both endogenous and exogenous
DNA damage.
Discussion
The lack of knowledge about the natural behavior and response
to therapy ofHNSCCs arising in patients with Fanconi anemia is a
major hindrance to their successful treatment. Therapy for
HNSCC includes surgery and possibly radiotherapy or chemo-
therapy, depending upon disease stage. In light of the established
sensitivity of patients with Fanconi anemia to genotoxic agents,
their poor survival has traditionally been attributed to intolerance
of therapy. However, long-term follow-up of patients who survive
initial therapy and obtain a complete response indicates a very
high rate of recurrence of 50% by age 40 (15). Most of these
recurrences are at the original site of disease, suggesting incom-
plete disease control rather than origination of a metachronous
tumor. Although the rate of second or multiple primary tumor
formation in patients with Fanconi anemia HNSCC had been
reported to be over 60% (15), the majority of these are in the
anogenital regions, further underscoring that tumors arising in the
head and neck area after a ﬁrst occurrence of HNSCC are likely to
be recurrent tumor. Given that current therapy provided for these
tumors may be insufﬁcient to provide lasting progression-free
survival, and that treatment of Fanconi anemia patients with
HNSCC could beneﬁt from an in-depth understanding of tumor
biology and response to therapy, we considered whether patients'
poor prognosis extends beyond their constitutional susceptibility
to DNA damage. To address this lack of understanding in human
and murine models, we utilized a panel of HNSCC cell lines
derived from the tumors of patients with Fanconi anemia or mice
and their Fanconi anemia–proﬁcient counterparts.
A signiﬁcant body of research has provided insight into the
behavior of Fanconi anemia hematopoietic cells. Bone marrow
transplantation for Fanconi anemia patients with severe bone
marrow failure, AML, or myelodysplastic syndrome can be suc-
cessfully performed with low rates of toxicity-related morbidity
using T-cell–depleted grafts and reduced-intensity preparative
regimens (41). Unfortunately, the hope that Fanconi anemia
HNSCC could also be treated both effectively and safely with
low-dose clastogenic therapies may be incorrect. Published
research suggests that the extrahematopoietic compartments of
these patients possess a distinct set of characteristics; for instance,
in both in vitro and in vivomodels of the epidermal compartment,
Fanconi anemia deﬁciency leads to unique and unexpected
gains in keratinocyte proliferation despite increasedDNAdamage
(17, 18).
Thorough understanding of Fanconi anemia HNSCC has been
impaired by the need of a comprehensive model. We used an
isogenic human Fanconi anemia HNSCCmodel that allowed for
observations of tumor cell characteristics that were strictly Fan-
coni anemia–dependent. Three-dimensional organotypic tumor
rafts utilized here provide a view of Fanconi anemia HNSCC as a
carcinoma in situ, and allow for quantiﬁable examination of
tumor cell proliferation in a physiologic but controlled environ-
ment. However, although available human Fanconi anemia
HNSCC cell lines are well characterized (19), they are few in
number. The difﬁculty in faithfully recapitulating the Fanconi
anemia epithelial compartment is underscored by the fact that
Fanconi anemia mice do not spontaneously form HNSCCs (42).
We thus used 4-NQO to induce HNSCCs in WT and Fancc/
mice. The cell lines isolated from these and nonmalignant oral
keratinocytes of WT and Fancc/mice reveal data similar to that
obtained in the human Fanconi anemia HNSCC cell system.
Figure 4.
ICL sensitivity of human Fanconi anemia HNSCC. A, MMC cellular
growth assaysof Fanconi anemia patient–derived (black) and sporadic (gray)
HNSCC cell lines indicate overlap of sensitivities following 5 days of
treatment. B, MMC EC50s of Fanconi anemia patient–derived and
sporadic HNSCC cell lines following 5 days of exposure; a t test revealed
no signiﬁcant difference.
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We ﬁnd that the growth characteristics between Fanconi ane-
mia–deﬁcient and Fanconi anemia–complemented HNSCC cells
are similar. In contrast, Fanconi anemia complementation of
patient-derived nonmalignant keratinocytes decreases hyperpla-
sia (17, 18). In light of the chromosomal instability induced by
Fanconi anemia deﬁciency, loss of the suppressive effect of the
Fanconi anemia pathway on proliferation of the premalignant
epithelium could conceivably contribute to the increased risk of
HNSCC in patients with Fanconi anemia. However, the loss of
growth suppression seen in Fanconi anemia–complemented
HNSCC cells suggests that, following malignant transformation,
cellular machineries become less dependent upon Fanconi ane-
mia deﬁciency.
Previous work utilized colony assays to explore the chemosen-
sitivity of Fanconi anemia compared with sporadic HNSCC cells,
and found a lack of MMC sensitivity in the FANCA-deﬁcient
OHSU-974 cell line (20). Importantly, the present study conﬁrms
this result. In contrast, ICL sensitivity has been observed in
Fanconi anemia ﬁbroblasts (5, 20, 43, 44). We postulated that,
in the background of Fanconi anemia deﬁciency, tumorigenesis
and the resulting genomically unstable environment, as illustrat-
ed by the complex karyotypes of Fancc/HNSCCs (Supplemen-
tary Table S1), could lead to adaptations in cellular processes that
may confer relative chemoresistance. Such adaptation is in line
with comparisons between murine keratinocytes versus HNSCC-
derived cell lines; early passage–immortalized oral keratinocytes
are consistently hypersensitive to ICLs, whereas HNSCC cell
populations are not (Fig. 3A–D). Alterations in DNA repair
mechanisms are one of a variety of means for tumor cells to
become chemoresistant, andwould be especially advantageous to
a cancer arising in a patient with intrinsicDNAdamage sensitivity.
It thus stands to reason that Fanconi anemia HNSCCs would, in
the process of tumor generation and development, and in
response to the increased cellular stress during transformation,
be preferentially selected for cells that have enhanced DNA repair
mechanisms.
Increased performance of NHEJ at the expense of HR is an
expected result of Fanconi anemia pathway loss and so is a natural
ﬁrst choice for examination of the impact of DNA repair on
chemosensitivity of Fanconi anemia HNSCCs. However, the
extent to which NHEJ participates in the survival of Fanconi
anemia HNSCC has not previously been explored, nor has DNA
repair by NHEJ been directly measured in Fanconi anemia
HNSCC cells. Using DNA repair reporter assays, we show that,
as expected, Fanconi anemia–deﬁcient VU-1131 cells exhibit
increased NHEJ (Fig. 5B). We found that DNA-PKcs inhibition
does not decrease the cisplatin EC50 of the human Fanconi
anemia–deﬁcient HNSCC cell lines (Fig. 5D), while all are uni-
formly sensitive to PARP inhibition. The lack of enhanced cis-
platin sensitivity of Fanconi anemia–deﬁcient HNSCC cells fol-
lowing DNA-PKcs inhibition suggests that Ku-dependent NHEJ is
not the DNA repair mechanism required by Fanconi anemia
HNSCC cells for repair of damage caused by ICLs.
In contrast with the NHEJ machinery, PARP appears to be a
more promising target in Fanconi anemia HNSCCs. We show
increased activation of PARP in Fanconi anemia–deﬁcient
HNSCC cells by greater formation of intranuclear PAR foci fol-
lowing MMC treatment (Fig. 6B and C). In addition, rescue of
PARP inhibitor sensitivity of human Fanconi anemia HNSCC
cells occurred by gene complementation (Fig. 6A; Supplementary
Fig. S4A), and uniform PARP inhibitor sensitivity was addition-
ally observed in murine Fanconi anemia HNSCC cells (Fig. 6D;
Supplementary Fig. S4B). PARP inhibitor sensitivity has previ-
ously been examined in MMC-sensitive ﬁbroblasts derived from
Fanconi anemia mice as well as patients with Fanconi anemia,
with conﬂicting results (5, 44); the present work adds to this not
only by showing PARP sensitivity in Fanconi anemiaHNSCC cells
but also by linking PARP activity to cellular response to ICLs and
Figure 5.
Preference for NHEJ of mutant and complemented Fanconi anemia HNSCC cells. A, schematic of DNA repair reporter assay constructs for NHEJ. B, reporter
assays performed on isogenic VU-1131 cells indicate that Fanconi anemia gene correction decreases baseline preference for NHEJ.  , P < 0.01 (t test). C, immunoblot
of total DNA-PKcs and pDNA-PKcsS2056 in FAmut and FAcomp cell lines treated with 2 mg/mL bleomycin for 20 minutes in the presence and absence of 24 hours
of pretreatment with the DNA-PKcs inhibitor NU-7026 (2 mmol/L). Pretreatment with NU-7026 decreases phosphorylation of DNA-PKcs caused by bleomycin
treatment. D, chemical inhibition of DNA-PKcs does not decrease the cisplatin EC50 of FAmut HNSCC cells relative to FAcomp cells following 2 days of exposure.
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subsequent relative resistance. We thus postulate that PARP
hyperactivation is amechanism frequently acquiredduringmalig-
nant transformation whereby Fanconi anemia HNSCC overcome
constitutional DNA damage sensitivity.
PARP activation could conceivably overcome Fanconi anemia
pathway deﬁciency by multiple mechanisms. PARP1, which
comprises approximately 90% of intranuclear PARP, engages
numerous modes of DNA repair, including single-strand break
repair (45), base excision repair (45), nucleotide excision repair
(46), Ku-independent NHEJ (37), and HR (47). PARP1 has also
been implicated in Chk1 signaling at stalled replication forks
(40), plays a role in control of transcription by maintaining
chromatin in a transcriptionally active state (48), and may pro-
mote survival by functioning as a cofactor for NF-kB–dependent
transcription (49). PARP2 has been associated with the later steps
of single-strand break repair and base excision repair (50). It
remains tobe seenwhat aspects of PARPprotein function aremost
critical for Fanconi anemia HNSCC cell adaptation.
The relative ICL resistance of Fanconi anemia HNSCC cells
highlights the delicate balance between providing effective ther-
apy and avoiding excessive toxicity in cancer treatment. The
difﬁculty in achieving this balance becomes especially profound
in patients with Fanconi anemia HNSCC, as the therapy de-
escalation that may be necessary to avoid overwhelming toxici-
ty-related morbidity may simultaneously undertreat their malig-
nancy. In this light, it is essential to identify new therapies thatwill
enhance survival of this fragile patient population. Identiﬁcation
of PARP-mediated DNA repair as a key survival mechanism
employed by Fanconi anemia HNSCCs provides a promising
new potential avenue of treatment. PARP inhibitor therapy could
enhance efﬁcacy of low-dose clastogenic treatments via synergistic
effects. PARP inhibition could greatly beneﬁt patients that have
undergone bone marrow transplantation that are at the highest
risk for HNSCC development, as the presence of a hematopoietic
compartment unaffected by Fanconi anemia could prevent exces-
sive myelotoxicity in a patient group with an otherwise grim
Figure 6.
PARP inhibitor sensitivity of human andmurine Fanconi anemia HNSCC cells. A, cellular growth assays on isogenic humanHNSCC cells exposed to the PARP1/PARP2
inhibitor olaparib showuniform sensitivity of FAmut cell lines.  ,P<0.05; ,P<0.01 (t test). B, immunoﬂuorescence for PAR foci in VU-1131 cells shows increasedPAR
foci formation in FAmut cells over a 24-hour course of MMC treatment. Results shown are representative of two (no treatment) or three (2, 4, and 24 hours)
independent experiments of each time point, each with similar results. C, quantiﬁcation of intranuclear PAR foci in VU-1131 cells over a 24-hour course of MMC
treatment reveals a signiﬁcantly increased number of PAR foci in FAmut cells at 4 hours of exposure.  , P < 0.01 (t test). D, cellular growth assays performed on
murine Fancc/ (M-SCC) and WT (W-SCC) HNSCC cell lines treated with olaparib show signiﬁcantly increased sensitivity of Fancc/ cell lines.  , P < 0.05.
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prognosis. Further studies targeting PARPwill hopefully allow for
forward progress in improvement of outcomes of Fanconi anemia
patients with HNSCC.
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